Your browser doesn't support javascript.
loading
From Consternation to Revelation: Discovery of a Role for IGSF1 in Pituitary Control of Thyroid Function.
Bernard, Daniel J; Brûlé, Emilie; Smith, Courtney L; Joustra, Sjoerd D; Wit, Jan M.
Afiliação
  • Bernard DJ; Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec H3G 1Y6, Canada.
  • Brûlé E; Department of Anatomy and Cell Biology, McGill University, Montréal, Québec H3A 0C7, Canada.
  • Smith CL; Department of Anatomy and Cell Biology, McGill University, Montréal, Québec H3A 0C7, Canada.
  • Joustra SD; Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec H3G 1Y6, Canada.
  • Wit JM; Department of Pediatrics, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands.
J Endocr Soc ; 2(3): 220-231, 2018 Mar 01.
Article em En | MEDLINE | ID: mdl-29594256
ABSTRACT
Immunoglobulin superfamily, member 1 (IGSF1) is a transmembrane glycoprotein highly expressed in the mammalian pituitary gland. Shortly after its discovery in 1998, the protein was proposed to function as a coreceptor for inhibins (and was even temporarily renamed inhibin binding protein). However, subsequent investigations, both in vitro and in vivo, failed to support a role for IGSF1 in inhibin action. Research on IGSF1 nearly ground to a halt until 2011, when next-generation sequencing identified mutations in the X-linked IGSF1 gene in boys and men with congenital central hypothyroidism. IGSF1 was localized to thyrotrope cells, implicating the protein in pituitary control of the thyroid. Investigations in two Igsf1 knockout mouse models converged to show that IGSF1 deficiency leads to reduced expression of the receptor for thyrotropin-releasing hormone (TRH) and impaired TRH stimulation of thyrotropin secretion, providing a candidate mechanism for the central hypothyroidism observed in patients. Nevertheless, the normal functions of IGSF1 in thyrotropes and other cells remain unresolved. Moreover, IGSF1 mutations are also commonly associated with other clinical phenotypes, including prolactin and growth hormone dysregulation, and macroorchidism. How the loss of IGSF1 produces these characteristics is unknown. Although early studies of IGSF1 ran into roadblocks and blind alleys, armed with the results of detailed clinical investigations, powerful mouse models, and new reagents, the field is now poised to discover IGSF1's function in endocrine tissues, including the pituitary and testes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Endocr Soc Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Endocr Soc Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Canadá